CVAC: Nilai perusahaan marang bathi resik CureVac Pharma

CureVac Pharma - logo grafis emiten CVAC

CureVac N.V. (CVAC) seeks to strengthen its position in the mRNA sector while overcoming a lack of profitability and intense market pressure. The company's monthly P/E dynamics illustrate progress in this strategy, where 6.40 represents the latest metric reading. However, growth rates are constrained by a reliance on external contractors for distribution and the ongoing implementation of automated RNA synthesis systems in laboratories.

CVAC - Pangali P/E CureVac ing rentang 27.11.2022 - 17.01.2026

Rincian analitis perusahaan CureVac Corp (CVAC)

- rega lan prakiraan konsensus rega:
Rega saham curevac.com|CVAC - Target konsensus
- informasi kapitalisasi pasar:
Nilai pasar CureVac N.V.|CVAC - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- indikator nilai aset resik miturut neraca:
Aset Bersih saben Siji Saham CureVac|CVAC - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku curevac.com|CVAC - Aset Agregat Perusahaan
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi CureVac N.V.|CVAC - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal CureVac Pharma|CVAC - Utang perusahaan|Utang-utang marang aset resik CureVac N.V.|CVAC - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan CureVac|Rasio cepet curevac.com
- statistik bathi lan rasio pasar:
CVAC - Bathi resik perusahaan|Penghasilan resik sing dikarepake CureVac N.V.|CVAC - Pangali P/E|Rasio prakiraan rega marang bathi CureVac NV|CVAC - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CureVac N.V.|CVAC - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) CureVac|CVAC - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan curevac.com|CVAC - Wutah bathi resik saben saham ing taun iki|Dinamika bathi saben saham sing diarepake ing taun ngarep CureVac N.V.
Analisis komprehensif perusahaan:CureVac N.V.
Barang unggulan CureVac Corp

Investors must filter risks for CureVac N.V. (CVAC) by evaluating the ratio of market value to net income via the business's P/E ratio to determine the investment payback period. Large-scale automation of RNA synthesis through laboratory robotics enhances operational efficiency, which is reflected in this chart, allowing for the differentiation of fundamental undervaluation from asset stagnation and confirming the long-term viability of the business model.

Pesaing wigati

Pangali P/E gilead.com|Koefisien rega marang bathi CDTX (Cidara Corp)|NVAX (Novavax Inc) - Nilai perusahaan marang bathi resik|Valneva Pharma - Koefisien rega marang bathi|Vir Corp - Rasio rega marang bathi|SIGA Technologies, Inc. - Pangali P/E|Periode bali modal bisnis emergentbiosolutions.com EBS|Atea Pharmaceuticals, Inc. (AVIR) - Rasio rega marang bathi|Invivyd - Nilai perusahaan marang bathi resik|Koefisien rega marang bathi ENTA|Pangali P/E Inovio Pharma|Rasio rega marang bathi HilleVax, Inc. (HLVX)|Periode bali modal bisnis kalaristx.com|Pangali P/E DYAI (Dyadic International, Inc.)|NNVC - Koefisien rega marang bathi|TLPH: Koefisien rega marang bathi|COCP - Pangali P/E|trawspharma.com (TRAW) - Rasio rega marang bathi|Dogwood Therapeutics - Nilai perusahaan marang bathi resik|QLGN (Qualigen Therapeutics, Inc.) - Pangali P/E|Kapitalisasi marang bathi AlloVir Bio ALVR|Koefisien rega marang bathi VBIV (VBI Vaccines Inc.)|Rasio rega marang bathi VIRI (virios.com)|Pangali P/E VXRT (Vaxart)